Skip to main content
Premium Trial:

Request an Annual Quote

Protein Chip Market Poised to Exceed $700M By 2006

NEW YORK, March 25 - The protein chip market is "poised for enormous growth" over the next four years, a recent industry study has found.

The three-month study, called Protein Biochips: On the Threshold of Success, predicts that sales of protein chips will exceed $700 million in 2006, a 10-fold increase from the $76 million in sales the industry recorded one year ago.


"With at least 25 companies either selling protein biochips today or preparing to enter the market within the next two years, sales in this industry are poised for enormous growth," according to BioInsights, which conducted the study.

In its report, released on Monday, BioInsights also compared interaction biochips with capture biochips, and pre-fabricated protein biochips with tools used to assemble biochips.

The report also examined the demand for protein chips in drug discovery, drug validation, therapeutic development, pre-clinical and clinical trials, and diagnostics.

Companies, academic centers, and government labs highlighted in the report include Archemix, Aspira Biosystems, Biacore, BioForce Nanosciences, BioInvent International, Biosite, Cambridge Antibody Technology, Ciphergen, Clontech, CombiMatrix, GeneScan, Glaucus Proteomics, HTS Biosystems, Harvard Medical Institute of Proteomics, Jerini, Large Scale Biology, Lawrence Livermore National Laboratory, NextGen Sciences, Packard BioScience, Phylos, Prolinx, Protagen, Protometrix, Randox, SomaLogic, TeleChem International, Van Andel Research Institute, Zeptosens, and Zyomyx.

 

In an interview with GenomeWeb, Felicia Gentile, president of Redwood City, Calif.-based BioInsights, said that although protein chips and DNA chips are complementary tools, "the reality is that people are now interested in the business end [of research]. And the proteins are the business end now."

 

She stressed, however, that this doesn't mean that researchers will be abandoning their DNA chips any time soon. "I do see more of an emphasis in the proteomics, but I don't see the DNA chip completely going away," said Gentile. "But I do think there will be less emphasis on them" in the coming months and years.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.